Voluntis and AstraZeneca have announced plans to test a digital support service for women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of cediranib plus olaparib
Voluntis developed the service in close clinical collaboration with AstraZeneca and the US National Cancer Institute (NCI).
It is delivered through a smartphone app paired with a web portal to help clinicians and patients manage side effects of hypertension and diarrhoea sometimes associated with combination therapy with cediranib and olaparib.
Such side effects are traditionally described to care teams through manual, time-consuming and non-digitised channels.
The app will be tested as a companion device in three separate clinical trials sponsored by the NCI beginning in the first quarter of 2016, under a cooperative research and development agreement between the NCI and AstraZeneca.
Antoine Yver, head of oncology, global medicines development at AstraZeneca, said: “Empowering patients with this smartphone-based app gives them greater control of their treatment and management of their response.
“The support it provides can further reduce medication dose modification and discontinuation rates and help maintain patients on therapy to improve their treatment outcome.”
Pierre Leurent, chief executive officer of Voluntis, said: “We are delighted to be partnering with AstraZeneca for this project as it has a strong focus on the use of companiondevices in drug development.
“AstraZeneca’s approach combined with our technological, medical and regulatory expertise provides the perfect synergy to create a personalised therapeutic solution that goes beyond the pill to best serve the needs of patients and their health care providers.”